Research article

Serum markers in interstitial pneumonia with and without *Pneumocystis jirovecii* colonization: a prospective study

Yasuo Shimizu*1,3,4, Noriaki Sunaga1, Kunio Dobashi2, Makoto Fueki3, Naoto Fueki3, Sohei Makino3,4 and Masatomo Mori1

Address: 1Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi Gunma 371-8511, Japan, 2Gunma University School of Health Sciences, 3-39-15 Showa-machi, Maebashi Gunma 371-8511, Japan, 3Jobu Hospital for Respiratory Disease 586-1 Taguchi-machi, Maebashi, Gunma 371-0048, Japan and 4WHO Collaborating Center of Prevention and Control of Chronic Respiratory Diseases, Dokkyo University, (DU-WCC) 880 Kitakobayashi Mibu Shimotsuga-gun, Tochigi 321-0293, Japan

Email: Yasuo Shimizu* - yasuos@med.gunma-u.ac.jp; Noriaki Sunaga - nsunaga@showa.gunma-u.ac.jp; Kunio Dobashi - dobashi@health.gunma-u.ac.jp; Makoto Fueki - ichiyokai-jkn@mvd.biglobe.ne.jp; Naoto Fueki - nao10-fue@pasoraku.jp; Sohei Makino - makino-tokyo-jobu@md.neweb.ne.jp; Masatomo Mori - mmori@med.gunma-u.ac.jp

* Corresponding author

Published: 22 April 2009

BMC Infectious Diseases 2009, 9:47 doi:10.1186/1471-2334-9-47

This article is available from: http://www.biomedcentral.com/1471-2334/9/47

© 2009 Shimizu et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

**Background:** In patients with chronic respiratory disease, *Pneumocystis jirovecii* (*P. jirovecii*) colonization is observed, and may influence disease progression and systemic inflammation. *Pneumocystis* pneumonia causes interstitial changes, so making a diagnosis of PCP in patients who have interstitial pneumonia (IP) with *P. jirovecii* colonization is sometimes difficult based on radiography.

**Methods:** This study investigated the prevalence of *P. jirovecii* colonization in IP patients and assessed pulmonary injury due to *P. jirovecii* colonization by measurement of serum markers (KL-6, SP-A, SP-D, and (1→3) β-D-glucan ([β-D-glucan])) and the peripheral lymphocyte counts, prospectively. A total of 75 patients with idiopathic pulmonary fibrosis (*n* = 29), collagen vascular-related interstitial pneumonia (*n* = 19), chronic bronchitis or pneumonia (*n* = 20), and *Pneumocystis* pneumonia (*n* = 7) were enrolled in this prospective study. *P. jirovecii* DNA was detected in sputum samples, while serum markers and the lymphocyte count were measured in the peripheral blood.

**Results:** IP patients (idiopathic pulmonary fibrosis and collagen vascular-related IP) who received oral corticosteroids had a high prevalence of *P. jirovecii* colonization (23.3%). In IP patients, oral corticosteroid therapy was a significant risk factor for *P. jirovecii* colonization (*P* < 0.05). Serum markers did not show differences between IP patients with and without *P. jirovecii* colonization. The β-D-glucan level and lymphocyte count differed between patients with *Pneumocystis* pneumonia or *P. jirovecii* colonization.

**Conclusion:** Serum levels of KL-6, SP-A, SP-D, and β-D-glucan were not useful for detecting *P. jirovecii* colonization in IP patients. However, the serum β-D-glucan level and lymphocyte count were useful for distinguishing *P. jirovecii* colonization from pneumocystis pneumonia in IP patients.
**Backgrounds**

*Pneumocystis jirovecii* (*P. jirovecii*) is a fungus, and a high prevalence of *P. jirovecii* colonization has been reported among non-human immunodeficiency virus (HIV)-infected immunocompetent patients with primary respiratory disease [1-3]. Interstitial pneumonia (IP) is also associated with a high colonization rate of *P. jirovecii* [4]. The mortality rate of patients with acute exacerbation of IP is 78% after hospital admission [5]. After acute exacerbation of IP occurs in IP patient with *P. jirovecii* colonization, it is difficult to distinguish IP associated with *Pneumocystis* pneumonia (PCP) from IP without PCP based on the clinical and radiological features. When *P. jirovecii* is detected in sputum or bronchoalveolar lavage (BAL) fluid from IP patients with exacerbation, the clinician has to determine whether the patient has infection or colonization by *P. jirovecii*, and whether treatment should include sulfamethoxazole/trimethoprim (ST). Serum levels of KL-6 [6], surfactant protein A (SP-A), and surfactant protein D (SP-D) are used as markers of active IP [7]. KL-6 is an epithelial mucin and also membrane glycoprotein classified as cluster 9. KL-6 is more prominent in injured type II pneumocytes, and leaked into blood flow [6,8]. SP-A and SP-D are calcium-dependent lectins, and prominently produced by type II pneumocytes and Clara cells in injured lung [9]. PCP infection leads the accumulation of neutrophils and CD8 lymphocytes, and elicits the inflammatory mediator of macrophage inflammatory protein (MIP)-2, interleukin (IL)-8, and tumor necrosis factor (TNF)-α [10,11]. Mechanisms of elevation of serum markers in PCP are thought that these mediators induce type II pneumocytes damages or hyperplasia, and this affects the elevations of KL-6, SP-A and SP-D on serum levels. Although elevation of serum levels of KL-6 and SP-A are reported in PCP, while elevation of the serum (1→3) β-D-glucan (β-D-glucan) level has been reported as a marker of PCP [12,13], whether these markers are affected by *P. jirovecii* colonization has not yet been investigated in IP patients. In the present study, we prospectively examined colonization by *P. jirovecii* in IP patients, including those with idiopathic pulmonary fibrosis (IPF) or collagen vascular disease-related interstitial pneumonia (CVD), and also examined *P. jirovecii* in patients with chronic bronchitis or pneumonia (CB/Pneumonia). Furthermore, we compared the levels of these serum markers between IP patients with or without *P. jirovecii* colonization to determine whether the markers were affected by colonization.

**Methods**

**Subjects**

A total of 75 patients were enrolled in this prospective study. The IPF group (n = 29, men/women = 18/11, age = 64.7 ± 10.2 years) included 22 patients with usual interstitial pneumonia (UIP) and 7 patients with non-specific interstitial pneumonia (NSIP). The CVD group (n = 19, men/women = 10/9, age = 63.6 ± 7.8 years) included 11 patients with rheumatoid arthritis, 3 with polymyositis, 2 with polyarteritis nodosa, 1 with dermatomyositis, 1 with mixed connective tissue disease, and 1 with Sjögren syndrome. The CB/Pneumonia group (n = 20) included 10 men and 10 women aged 66.8 ± 9.5 years. The PCP group (n = 7, men/women = 4/3, age = 61.6 ± 10.8 years) included 1 patient with ulcerative colitis, 3 with lung cancer, 1 with adrenal deficiency, 1 with human immunodeficiency virus, and 1 with polymyositis. The numbers of patients who received the oral corticosteroid therapy were 11 patients in UIP, 5 patients in NSIP, 14 patients in CVD and 1 patient in PCP. The diagnosis of IPF was made using the American Thoracic Society/European Respiratory Society (ATS/ERS) International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonias [14]. PCP was diagnosed from the detection of *P. jirovecii* DNA in sputum or BAL by PCR, typical radiographic features, typical symptoms [15], and the course of chest symptoms and pulmonary changes on CT or chest radiographs. A diagnosis of *P. jirovecii* colonization was based on the detection of *P. jirovecii* DNA in induced sputum by PCR, no changes of chest X-ray films or chest CT scans for two months, no change of oxygen saturation for two months, no past or current PCP infection or HIV infection, no treatment with ST for PCP, and no clinical signs of PCP [16]. Patients receiving oral corticosteroids at doses above 5 mg/day were defined as the IP patients on corticosteroid therapy. This study was conducted according to the guidelines of the Declaration of Helsinki and approved by institutional review board. All of the patients are given written informed consent.

**Laboratory tests**

Induced sputum samples were collected after inhalation of ultrasonically nebulized hypertonic saline. Sputum samples were subjected to PCR according to the method of Wakefield et al [17,18] using AmpliTaq DNA polymerase (Roche Diagnostics, Switzerland) and a PJ-2000 thermal cycler (Perkin Elmer, U.S.A.). A peripheral blood sample was collected, and the lymphocyte count, CD4 T cell count, and serum KL-6 level were measured as described previously [19]. SP-A and SP-D were measured by using the SP-A test Kokusai F kit (Sysmex, Japan) and SP-D Yamasa EIA kit (Yamasa, Japan), respectively [7,20]. β-D-glucan was measured by the β-D-glucan test (Wako, Japan) based on a kinetic turbidmetric assay [21].

**Statistics**

Categorical data were compared by using the chi-squared test or Fisher’s exact test. The significance of differences between groups was calculated by Dunnett’s test after the Kruskal-Wallis test. The relation of oral corticosteroid therapy (odds ratio) to *P. jirovecii* colonization was calculated by using the chi-squared test for comparison between IP patients receiving oral corticosteroids and those not on corticosteroid therapy. The significance of
differences between IP patients on oral corticosteroid therapy with *P. jirovecii* colonization and IP patients on corticosteroid therapy without *P. jirovecii* colonization was calculated by the Man-Whitney test. Statistical significance was defined as $P<0.05$.

**Results**

**The rate of *P. jirovecii* colonization on pulmonary diseases**

The *P. jirovecii* colonization rates were 13.8% in the IPF group and 15.8% in CVD group, while it was 0% in the CB/Pneumonia group. The *P. jirovecii* colonization rate of IP patients on oral corticosteroid therapy (n = 30), i.e., IPF and CVD patients on corticosteroids with *P. jirovecii* colonization, was significantly higher (23.3%) than the rate (0%) for IP patients (n = 18) who were not on corticosteroids (Fig. 1a). The odds ratio for *P. jirovecii* colonization in IP patients receiving oral corticosteroids was 16.3 ($P = 0.0097$). The use of oral corticosteroids was high in patients with IPF (55.2%) and CVD (73.7%), and the rate was not significantly different between the IPF group and the CVD group. None of the CB/pneumonia patients were on oral corticosteroid therapy, and only one patient was receiving oral corticosteroids in the PCP group (Fig. 1b).

**Serum marker levels and lymphocytes count in pulmonary diseases**

Serum levels of KL-6 were higher in the IPF (1278.5 ± 740.4) and PCP (1488 ± 1086.1) groups than in the CB/Pneumonia group (375.8 ± 300.8). The KL-6 level of the CVD group (898.2 ± 605.3) was not different from that of the PCP group (Fig. 2a). SP-A levels did not show significant differences among the IPF group (88.7 ± 36.2), CVD group (73.2 ± 52.1), CB/Pneumonia group (73.3 ± 41.4), and PCP group (121.9 ± 24.7) (Fig. 2b). SP-D levels did not show significant differences among the IPF group (166.9 ± 111.1), CVD group (92.7 ± 67.7), CB/Pneumonia group (131 ± 71.0), and PCP group (194.1 ± 157.5) (Fig. 2c). The $\beta$-D-glucan level of the PCP (32.8 ± 35.1) was significantly higher than that of the other groups (the IPF, CVD, and CB/pneumonia groups all had levels under the detection limit of <34) (Fig. 2d). Levels of serum markers did not show any significant differences between IP patients with and without *P. jirovecii* colonization on oral corticosteroid therapy with respect to KL-6 (1370 ± 810.4 vs. 1030.6 ± 594.6), SP-A (86.6 ± 32.8 vs. 73.5 ± 44.5), SP-D (142.8 ± 145.1 vs. 102.3 ± 121.9), and $\beta$-D-glucan (both groups were under the detection limit) (Figs. 2e, f, g and 2h). The lymphocyte count of the PCP group (397.1 ± 151.6) was significantly lower than those of the other groups (IPF: 1480.2 ± 917.1; CVD: 1543.8 ± 919.6; and CB/pneumonia: 1118.4 ± 445.3). CD4 T cell counts showed no statistical differences among the four groups (IPF: 614.8 ± 469; CVD: 711.8 ± 431.1; CB/pneumonia: 403.3 ± 369.9; and PCP: 129 ± 96.7) (Figs. 3a, b). The lymphocyte count and CD4 T cell count showed no statistical differences between IP patients with and without *P. jirovecii* colonization on oral corticosteroids (Figs. 3c, d). The peripheral lymphocyte count of the former group was 1206.7 ± 859.7 and that of the latter group was 1144.6 ± 560.0, while the CD4 T cell count was 651.6 ± 565.6 and 401.5 ± 235.4, respectively.

**Discussion**

*P. jirovecii* colonization occurs in patients with chronic respiratory disease, even in the absence of HIV infection [22]. The *P. jirovecii* colonization rate is 15.5% in pregnant women [23] and 10% to 40% in chronic obstructive disease (COPD) patients [1,24,25]. In the present study, IP patients who received oral corticosteroid therapy had a high *P. jirovecii* colonization rate of 23.3%. Oral steroid therapy was a statistical risk factor for *P. jirovecii* colonization. Furthermore, the serum $\beta$-D-glucan level and the lymphocyte count were useful to distinguish IP with *P. jirovecii* colonization patients from PCP patients, while serum SP-A, SP-D, and KL-6 levels were not useful. These serum markers were not affected by *P. jirovecii* colonization.

$\beta$-D-glucan is a major component of the *P. jirovecii* cyst wall [26]. Infection is established by adhesion of the trophic form of *Pneumocystis* to the alveolar epithelium, where it proliferates [27]. One of the reasons for the different levels of $\beta$-D-glucan in PCP and *P. jirovecii* colonization was considered to be *Pneumocystis* proliferation. Cyst wall $\beta$-D-glucan is partly responsible for the inflammatory response in the lung [28,29]. SP-A and SP-D levels
were reported to be affected by PCP infection via inflammatory mediators [10,11] or reported to influence on PCP infection, and to play a role in host defenses against *P. jirovecii* [30-32]. Based on these reports, we examined serum KL-6, SP-A, and SP-D levels in IP patients with or without *P. jirovecii* colonization on oral corticosteroids. Our results indicated that these markers did not show any difference between IP patients with and without *P. jirovecii* colonization, suggesting that KL-6, SP-A, and SP-D levels were not affected by *P. jirovecii* colonization in IP patients. Although there has been a report that *P. jirovecii* colonization plays a role in systemic inflammation in COPD patients [33], we did not examine the effect of *P. jirovecii* on other cytokines or on disease progression. To determine the effect of *P. jirovecii* colonization on serum markers, it would be necessary to compare the changes of each marker when new *P. jirovecii* colonization occurs in a patient. Since present study did not show the affect of *P. jirovecii* colonization on serum markers of KL-6, SP-A and SP-D, we could not determine the value of prophylaxis with ST for IP patients with *P. jirovecii* colonization against pulmonary injury. There are unsolved problems regarding droplet transmission of *P. jirovecii* and the existence of drug-resistant organisms associated with prophylaxis of ST. Further analysis will be needed to determine the efficacy of ST prophylaxis for IP patients with *P. jirovecii* colonization on oral corticosteroid therapy.

Recently, quantification of *P. jirovecii* DNA by real-time PCR targeting the heat shock protein 70 gene was reported to be useful for discrimination between colonization and infection with this organism [34]. When *P. jirovecii* is
detected in sputum or bronchoalveolar lavage (BAL) fluid from a patient with exacerbation of IP, the clinician has to determine whether a patient has infection or colonization. To make a diagnosis of PCP, real-time PCR of the HSP 70 gene might be used in the clinical setting.

Conclusion
In conclusion, serum markers (KL-6, SP-A, and SP-D) were not higher in IP patients with P. jiroveci colonization than in those without colonization. IP patients receiving oral corticosteroid therapy had a high prevalence of P. jiroveci colonization, and oral corticosteroids are a risk factor for colonization. When patients develop exacerbation of IP, to diagnosis PCP or P. jiroveci colonization, it seems to be useful to know in advance whether the patient is a carrier of P. jiroveci, and to also examine the serum β-D-glucan level and the peripheral lymphocyte count.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Yasu Shimizu MD., PhD: Design, Gathering Data, Statistical Analysis and Preparation of manuscript, Noriaki Sunaga MD., PhD: Gathering Data, Statistical Analysis, Kunio Dobashi MD., Prof: Reviewing Manuscript, Makoto Fueki MD: Gathering Data, Naoto Fueki MD., PhD: Gathering Data, Sohei Makino MD., Prof: Reviewing Manuscript, Masatomo Mori MD., Prof: Reviewing Manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors thank medical staffs of Gunma University and Jobu hospital for their expert assistance.

References
1. Probst M, Ries H, Schmidt-Wieland T, Serr A: Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 2000, 19:644-645.
2. Sing A, Roggenkamp A, Autenrieth IB, Heesemann J: Pneumocystis carinii carriage in immunocompetent patients with primary pulmonary disorders as detected by single or nested PCR. J Clin Microbiol 1999, 37:3409-3410.
3. Maskell NA, Waine DJ, Lindley A, Pepperell JC, Wakefield AE, Miller RF, Davies RJ: Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 2003, 58:594-597.
4. Vidal S, de la Horra C, Martin J, Montes-Cano MA, Rodriguez E, Rodriguez F, Varela JM, Piedrano FJ, Calderón EJ: Pneumocystis jiroveci colonisation in patients with interstitial lung disease. Clin Microbiol Infect 2006, 12:231-235.
5. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T: Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006, 27:143-150.
6. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989, 96:68-73.
7. Takahashi H, Kuroki Y, Tanaka H, Saito T, Kurokawa K, Chiba H, Sagawa A, Nagae H, Abe S: Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000, 162:258-263.
8. Hirashawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K: KL-6, a human MUC1 mucin, is chemotactic for human fibroblast. Am J Respir Cell Mol Biol 1997, 17:501-507.
9. Herrmans C, Bernard A: Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med 1999, 159:646-678.
10. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG: Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999, 104:1307-1317.
11. Hiyama G, Hiyama H, Hiyama T, Hiyama M: KL-6 as a serologic indicator of Pneumocystis carinii pneumonia in immunocompromised hosts. Intern Med 1992, 21:501-507.
12. Hermans C, Bernard A: Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med 1999, 159:646-678.
13. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG: Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999, 104:1307-1317.
Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/9/47/prepub

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

13. Phelps DS, Rose RM: Increased recovery of surfactant protein A in AIDS-related pneumonia. Am Rev Respir Dis 1991, 143:1075-1078.
14. American Thoracic Society; European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002, 165:277-304.
15. Thomas CF Jr, Limper AH: Pneumocystis pneumonia. N Engl J Med 2004, 350:2487-2498.
16. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, Huang L, Beard CB, Kaplan JE: Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004, 10:1713-1720.
17. Wakefield AE, Pixley FJ, Banerji S, Sinclair K, Miller RF, Moxon ER, Hopkin JM: Detection of Pneumocystis carinii with DNA amplification. Lancet 1990, 336:451-453.
18. Wakefield AE, Guiver L, Miller RF, Hopkin JM: DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet 1991, 337:1378-1379.
19. Shimizu Y, Kuwabara H, Ono A, Higuchi S, Hisada T, Dobashi K, Utsugi M, Mitai Y, Mori M: Intracellular Th1/Th2 balance of pulmonary CD4(+) T cells in patients with active interstitial pneumonia evaluated by serum KL-6. Immunopharmacol Immunotoxicol 2006, 28:295-304.
20. Al-Salmi QA, Walter JN, Colarusso GN, Sockrider MM, Smith EO, Takahashi H, Fan LL: Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease. Chest 2005, 127:403-407.
21. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, Ishizaka A: Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007, 131:1173-1180.
22. Huang L, Morris A, Limper AH, Beck JM, ATS Pneumocystis Workgroup Participants: An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006, 3:655-664.
23. Vargas SL, Ponce CA, Sanchez CA, Ullrea AV, Bustamante R, Juarez G: Pregnancy and asymptomatic carriage of Pneumocystis jiroveci. Emerg Infect Dis 2003, 9:605-606.
24. Calderon EJ, Regordan C, Medrano FJ, Ollero M, Varela JM: Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet 1996, 349:977.
25. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, Hogg JC, Huang L, Norris KA: Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004, 170:408-413.
26. Douglas CM: Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001, 39:55-66.
27. Burgess JW, Kottom TJ, Limper AH: Pneumocystis carinii exhibits a conserved meiotic control pathway. Infect Immun 2008, 76:417-425.
28. Carmona EM, Vassallo R, Vuk-Pavlovic Z, Standing JE, Kottom TJ, Limper AH: Pneumocystis cell wall beta-glucans induce dendritic cell costimulatory molecule expression and inflammatory activation through a Fas-Fas ligand mechanism. J Immunol 2006, 177:459-467.
29. Evans SE, Hahn PY, McCann F, Kottom TJ, Pavlovic ZV, Limper AH: Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am J Respir Cell Mol Biol 2005, 32:490-497.
30. Atochina EN, Beck JM, Hazeku A, Inch A, Kadire H, Tomer Y, Davis CA, Preston AM, Poulain F, Hawgood S, Beers MF: Enhanced lung injury and delayed clearance of Pneumocystis carinii in surfactant protein A-deficient mice: attenuation of cytokine responses and reactive oxygen-nitrogen species. Infect Immun 2004, 72:6002-6011.
31. Phelps DS, Umstead TM, Rose RM, Fishman JA: Surfactant protein A levels increase during Pneumocystis carinii pneumonia in the rat. Eur Respir J 1996, 9:565-570.
32. Vuk-Pavlovic Z, Mo EK, Icenhour CR, Standing JE, Fisher JH, Limper AH: Surfactant protein D enhances Pneumocystis infection in immune-suppressed mice. Am J Physiol Lung Cell Mol Physiol 2006, 290:L442-L449.
33. Calderon EJ, Rivera L, Respaldiza N, Morilla R, Montes-Cano MA, Friaza V, Munoz-Lobato F, Varela JM, Medrano FJ, Horra Cde L: Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect 2007, 45:171-179.